Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Investors Business Daily
Investors Business Daily
Business
INVESTOR'S BUSINESS DAILY

Phibro Animal Health Sees Its Composite Rating Rise To 96

Phibro Animal Health saw its IBD SmartSelect Composite Rating rise to 96 Tuesday, up from 92 the day before.

The upgrade means the stock currently tops 96% of all other stocks in terms of key performance metrics and technical strength. History shows the top market performers tend to have a 95 or higher score as they launch their major moves.

Phibro Animal Health is not currently near a proper buy zone. See if the stock goes on to form a new chart pattern and offer a new buying opportunity. Note that it is a thinly traded stock, with average daily dollar volume under $8 million.

Discover The 3 Keys To Successful Stock Investing

The stock has a 92 EPS Rating, which means its recent quarterly and longer-term annual earnings growth tops 92% of all stocks.

Its Accumulation/Distribution Rating of B- shows moderate buying by institutional investors over the last 13 weeks.

The company reported 64% EPS growth for Q2. Revenue growth climbed 24%, up from 13% in the prior report. The company has now posted increasing growth in each of the last two reports.

Phibro Animal Health holds the No. 1 rank among its peers in the Medical-Ethical Drugs industry group. Jazz Pharmaceuticals and Novartis ADR are also among the group's highest-rated stocks.

This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.